File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant
  • Basic View
  • Metadata View
  • XML View
TitleInduction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant
 
AuthorsZhao, G1 2
Du, L3
Xiao, W1
Sun, S1
Lin, Y2
Chen, M2
Kou, Z1
He, Y3
Lustigman, S3
Jiang, S3
Zheng, BJ2
Zhou, Y1
 
KeywordsASP-1
H5N1
M2e
Vaccine
 
Issue Date2010
 
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
 
CitationVaccine, 2010, v. 28 n. 44, p. 7233-7240 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2010.08.049
 
AbstractOur previous studies have shown the adjuvanticity of an Onchocerca volvulus recombinant protein, Ov-ASP-1 (ASP-1), when administered in an aqueous formulation with bystander vaccine antigens or commercial vaccines. In this study, we reported a novel formulation that took advantage of the protein nature of the ASP-1 adjuvant by creating recombinant fusion protein vaccines linking the highly conserved extracellular domain of M2 protein (M2e) consensus sequence of H5N1 influenza viruses with the ASP-1 adjuvant. Two recombinant fusion proteins designated M2e-ASP-1 and M2e3-ASP-1 were studied, in which ASP-1 was fused with one or three tandem copies of the M2e antigen. Our results show that these novel recombinant influenza vaccines, particularly M2e3-ASP-1, induced strong anti-M2e-specific humoral and cellular immune responses in the established mouse model. Furthermore, M2e3-ASP-1 was able to provide significant cross-clade protection against divergent H5N1 viruses. Consequently, this study has demonstrated a potential novel vaccine formulation that could provide a complementary prophylactic strategy in preventing the threat of future influenza outbreak resulting from rapid evolution of the H5N1 virus and co-circulation of multiple antigenic variants in various regions. © 2010 Elsevier Ltd.
 
ISSN0264-410X
2012 Impact Factor: 3.492
2012 SCImago Journal Rankings: 1.360
 
DOIhttp://dx.doi.org/10.1016/j.vaccine.2010.08.049
 
ISI Accession Number IDWOS:000283980400015
Funding AgencyGrant Number
National 863 Program of China2006AA02Z406
National 973 Program of China2005CB523001
NSFC30901371
Mega-projects of Science Research2009ZX10004-401
University Grants CommitteeAoE/M-12/06
Research Fund for the Control of Infectious Diseases, Hong Kong SAR09080812
Funding Information:

This study was supported by National 863 Program of China (2006AA02Z406), National 973 Program of China (2005CB523001), NSFC (30901371), Mega-projects of Science Research for the 11th Five-Year Plan (2009ZX10004-401), the Area of Excellence Scheme of the University Grants Committee (Grant AoE/M-12/06) and Research Fund for the Control of Infectious Diseases (09080812), Hong Kong SAR.

 
ReferencesReferences in Scopus
 
GrantsControl of Pandemic and Inter-pandemic Influenza
Cross-protective efficacy of immunization with different forms of M2 vaccines and their combinations with HA vaccines against highly pathogenic H5N1 influenza A viruses in mice
 
DC FieldValue
dc.contributor.authorZhao, G
 
dc.contributor.authorDu, L
 
dc.contributor.authorXiao, W
 
dc.contributor.authorSun, S
 
dc.contributor.authorLin, Y
 
dc.contributor.authorChen, M
 
dc.contributor.authorKou, Z
 
dc.contributor.authorHe, Y
 
dc.contributor.authorLustigman, S
 
dc.contributor.authorJiang, S
 
dc.contributor.authorZheng, BJ
 
dc.contributor.authorZhou, Y
 
dc.date.accessioned2011-07-27T01:31:07Z
 
dc.date.available2011-07-27T01:31:07Z
 
dc.date.issued2010
 
dc.description.abstractOur previous studies have shown the adjuvanticity of an Onchocerca volvulus recombinant protein, Ov-ASP-1 (ASP-1), when administered in an aqueous formulation with bystander vaccine antigens or commercial vaccines. In this study, we reported a novel formulation that took advantage of the protein nature of the ASP-1 adjuvant by creating recombinant fusion protein vaccines linking the highly conserved extracellular domain of M2 protein (M2e) consensus sequence of H5N1 influenza viruses with the ASP-1 adjuvant. Two recombinant fusion proteins designated M2e-ASP-1 and M2e3-ASP-1 were studied, in which ASP-1 was fused with one or three tandem copies of the M2e antigen. Our results show that these novel recombinant influenza vaccines, particularly M2e3-ASP-1, induced strong anti-M2e-specific humoral and cellular immune responses in the established mouse model. Furthermore, M2e3-ASP-1 was able to provide significant cross-clade protection against divergent H5N1 viruses. Consequently, this study has demonstrated a potential novel vaccine formulation that could provide a complementary prophylactic strategy in preventing the threat of future influenza outbreak resulting from rapid evolution of the H5N1 virus and co-circulation of multiple antigenic variants in various regions. © 2010 Elsevier Ltd.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationVaccine, 2010, v. 28 n. 44, p. 7233-7240 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2010.08.049
 
dc.identifier.citeulike7716681
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.vaccine.2010.08.049
 
dc.identifier.epage7240
 
dc.identifier.hkuros188636
 
dc.identifier.isiWOS:000283980400015
Funding AgencyGrant Number
National 863 Program of China2006AA02Z406
National 973 Program of China2005CB523001
NSFC30901371
Mega-projects of Science Research2009ZX10004-401
University Grants CommitteeAoE/M-12/06
Research Fund for the Control of Infectious Diseases, Hong Kong SAR09080812
Funding Information:

This study was supported by National 863 Program of China (2006AA02Z406), National 973 Program of China (2005CB523001), NSFC (30901371), Mega-projects of Science Research for the 11th Five-Year Plan (2009ZX10004-401), the Area of Excellence Scheme of the University Grants Committee (Grant AoE/M-12/06) and Research Fund for the Control of Infectious Diseases (09080812), Hong Kong SAR.

 
dc.identifier.issn0264-410X
2012 Impact Factor: 3.492
2012 SCImago Journal Rankings: 1.360
 
dc.identifier.issue44
 
dc.identifier.openurl
 
dc.identifier.pmid20732469
 
dc.identifier.scopuseid_2-s2.0-77957821697
 
dc.identifier.spage7233
 
dc.identifier.urihttp://hdl.handle.net/10722/135278
 
dc.identifier.volume28
 
dc.languageeng
 
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofVaccine
 
dc.relation.projectControl of Pandemic and Inter-pandemic Influenza
 
dc.relation.projectCross-protective efficacy of immunization with different forms of M2 vaccines and their combinations with HA vaccines against highly pathogenic H5N1 influenza A viruses in mice
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAdjuvants, Immunologic - administration and dosage - pharmacology
 
dc.subject.meshAntigens, Helminth - administration and dosage - immunology
 
dc.subject.meshHelminth Proteins - administration and dosage - immunology
 
dc.subject.meshInfluenza A Virus, H5N1 Subtype - immunology
 
dc.subject.meshInfluenza Vaccines - immunology
 
dc.subjectASP-1
 
dc.subjectH5N1
 
dc.subjectM2e
 
dc.subjectVaccine
 
dc.titleInduction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Zhao, G</contributor.author>
<contributor.author>Du, L</contributor.author>
<contributor.author>Xiao, W</contributor.author>
<contributor.author>Sun, S</contributor.author>
<contributor.author>Lin, Y</contributor.author>
<contributor.author>Chen, M</contributor.author>
<contributor.author>Kou, Z</contributor.author>
<contributor.author>He, Y</contributor.author>
<contributor.author>Lustigman, S</contributor.author>
<contributor.author>Jiang, S</contributor.author>
<contributor.author>Zheng, BJ</contributor.author>
<contributor.author>Zhou, Y</contributor.author>
<date.accessioned>2011-07-27T01:31:07Z</date.accessioned>
<date.available>2011-07-27T01:31:07Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>Vaccine, 2010, v. 28 n. 44, p. 7233-7240</identifier.citation>
<identifier.issn>0264-410X</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/135278</identifier.uri>
<description.abstract>Our previous studies have shown the adjuvanticity of an Onchocerca volvulus recombinant protein, Ov-ASP-1 (ASP-1), when administered in an aqueous formulation with bystander vaccine antigens or commercial vaccines. In this study, we reported a novel formulation that took advantage of the protein nature of the ASP-1 adjuvant by creating recombinant fusion protein vaccines linking the highly conserved extracellular domain of M2 protein (M2e) consensus sequence of H5N1 influenza viruses with the ASP-1 adjuvant. Two recombinant fusion proteins designated M2e-ASP-1 and M2e3-ASP-1 were studied, in which ASP-1 was fused with one or three tandem copies of the M2e antigen. Our results show that these novel recombinant influenza vaccines, particularly M2e3-ASP-1, induced strong anti-M2e-specific humoral and cellular immune responses in the established mouse model. Furthermore, M2e3-ASP-1 was able to provide significant cross-clade protection against divergent H5N1 viruses. Consequently, this study has demonstrated a potential novel vaccine formulation that could provide a complementary prophylactic strategy in preventing the threat of future influenza outbreak resulting from rapid evolution of the H5N1 virus and co-circulation of multiple antigenic variants in various regions. &#169; 2010 Elsevier Ltd.</description.abstract>
<language>eng</language>
<publisher>Elsevier Ltd. The Journal&apos;s web site is located at http://www.elsevier.com/locate/vaccine</publisher>
<relation.ispartof>Vaccine</relation.ispartof>
<subject>ASP-1</subject>
<subject>H5N1</subject>
<subject>M2e</subject>
<subject>Vaccine</subject>
<subject.mesh>Adjuvants, Immunologic - administration and dosage - pharmacology</subject.mesh>
<subject.mesh>Antigens, Helminth - administration and dosage - immunology</subject.mesh>
<subject.mesh>Helminth Proteins - administration and dosage - immunology</subject.mesh>
<subject.mesh>Influenza A Virus, H5N1 Subtype - immunology</subject.mesh>
<subject.mesh>Influenza Vaccines - immunology</subject.mesh>
<title>Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0264-410X&amp;volume=28&amp;issue=44&amp;spage=7233&amp;epage=7240&amp;date=2010&amp;atitle=Induction+of+protection+against+divergent+H5N1+influenza+viruses+using+a+recombinant+fusion+protein+linking+influenza+M2e+to+Onchocerca+volvulus+activation+associated+protein-1+(ASP-1)+adjuvant</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.vaccine.2010.08.049</identifier.doi>
<identifier.pmid>20732469</identifier.pmid>
<identifier.scopus>eid_2-s2.0-77957821697</identifier.scopus>
<identifier.hkuros>188636</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-77957821697&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>28</identifier.volume>
<identifier.issue>44</identifier.issue>
<identifier.spage>7233</identifier.spage>
<identifier.epage>7240</identifier.epage>
<identifier.isi>WOS:000283980400015</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<relation.project>Control of Pandemic and Inter-pandemic Influenza</relation.project>
<relation.project>Cross-protective efficacy of immunization with different forms of M2 vaccines and their combinations with HA vaccines against highly pathogenic H5N1 influenza A viruses in mice</relation.project>
<identifier.citeulike>7716681</identifier.citeulike>
</item>
Author Affiliations
  1. Institute of Microbiology Chinese Academy of Sciences
  2. The University of Hong Kong
  3. New York Blood Center